Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Part of paid clinical trials in Kansas City, Missouri.

Sponsor
Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
Study ID
NCT07209410
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Brimonidine Tartrate Ophthalmic 0.025% — DRUG
    Lumify is an approved eye drop to minimize ocular hyperemia.

Study Details

To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.

Key Dates

Start date
Nov 1, 2025
Status verified
Nov 2025
Primary completion
Dec 15, 2026
Completion
Jun 1, 2027

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Brimonidine Tartrate
    Patients experiencing hyperemia greater than grade 2 on Efron scale will receive brimonidine tartrate (Lumify). Photo documentation of hyperemia and patient satisfaction questionnaires will be administered.

Primary Outcome Measure

Effron Grading scale of ocular redness [ Time Frame: 2 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vision SourceKansas CityMissouri64111
Megan Hefter Research Coordinator
[email protected]
816-531-9100

Find similar trials in Kansas City, MO

By condition
Glaucoma
By specialty
Ophthalmology
By research site
Vision Source· Kansas City, MO

Related Studies